Drug Profile
Research programme: quadruplex oligonucleotides - Advanced Cancer Therapeutics
Alternative Names: PU 27Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator University of Louisville
- Developer Advanced Cancer Therapeutics
- Class Oligonucleotides
- Mechanism of Action Glycolysis modulators; Proto-oncogene protein c-myc modulators; Telomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Cancer in USA (unspecified route) (Advanced Cancer Therapeutics pipeline, February 2023)
- 28 Sep 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 08 Sep 2016 PU 27 is still in Preclinical development for Cancer in USA (Advanced Cancer Therapeutics, September 2016)